This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Jay Keasling | |
|---|---|
| Name | Jay Keasling |
| Birth date | 1961 |
| Birth place | Moscow, Idaho |
| Fields | Biochemical engineering, Synthetic biology, Metabolic engineering |
| Workplaces | University of California, Berkeley, Lawrence Berkeley National Laboratory, Amyris, LS9, Genomatica, UC Berkeley College of Chemistry |
| Alma mater | University of Idaho, Washington State University, University of Illinois Urbana-Champaign |
| Known for | Polyketide synthesis, artemisinin pathway engineering, metabolic pathway optimization |
Jay Keasling is an American biochemical engineer and a leading figure in synthetic biology and metabolic engineering, noted for engineering microbial pathways to produce pharmaceuticals, biofuels, and commodity chemicals. He holds faculty positions at University of California, Berkeley and leadership roles at Lawrence Berkeley National Laboratory, and has founded multiple biotechnology startups translating laboratory-scale innovations into industrial processes. His work bridges academic research, industrial biotechnology, and global health initiatives.
Keasling was born in Moscow, Idaho and raised in the Palouse before earning a Bachelor of Science at the University of Idaho and a Master of Science at Washington State University. He completed his doctorate at the University of Illinois Urbana-Champaign under advisors active in chemical engineering and biotechnology, and conducted postdoctoral research that connected to themes in metabolic engineering and protein engineering. During his formative years he interacted with faculty and researchers affiliated with institutions such as Sandia National Laboratories, Pacific Northwest National Laboratory, and networks tied to the Department of Energy. His education placed him in contact with researchers from Massachusetts Institute of Technology, California Institute of Technology, and Stanford University, situating him within a cohort that included contributors to bioprocess engineering and systems biology.
Keasling's laboratory advanced methods in metabolic engineering to reconstitute complex biosynthetic pathways in heterologous hosts such as Escherichia coli and Saccharomyces cerevisiae. His team engineered the biosynthesis of the antimalarial precursor artemisinic acid by integrating enzymes from organisms including Artemisia annua and microbial sources, employing strategies drawn from enzyme engineering, protein expression, and pathway optimization. This work intersected with initiatives at organizations such as Institute for OneWorld Health, Bill & Melinda Gates Foundation, and the World Health Organization to address malaria through scalable production methods. Keasling contributed to foundational tools in synthetic biology including standardized genetic parts, regulatory element libraries, and metabolic flux analysis techniques used in projects at Joint BioEnergy Institute and BioBricks Foundation. His group published advances in elucidating and manipulating polyketide synthases and nonribosomal peptide synthetases, connecting to research by teams at Harvard University, University of Cambridge, and ETH Zurich. Collaborative efforts linked his work to efforts at Novartis, GlaxoSmithKline, Pfizer, and Merck on biopharmaceutical production, while method development informed emergent platforms at Broad Institute and Salk Institute.
Keasling co-founded and advised multiple biotechnology companies translating academic discoveries into commercial technologies, including Amyris, LS9, and ventures partnered with firms like TotalEnergies, Royal Dutch Shell, and BASF. These startups developed microbial production routes for biofuels, specialty chemicals, and pharmaceutical precursors, interacting with industrial players such as DuPont, Cargill, Dow Chemical Company, and BP for scale-up and commercialization. His entrepreneurship connected to venture capital ecosystems involving firms like Kleiner Perkins, Sequoia Capital, and Andreessen Horowitz, and to incubators and technology transfer offices at University of California Office of the President. He engaged with public-private partnerships including collaborations with DARPA, Defense Advanced Research Projects Agency, and initiatives supported by the National Institutes of Health and the National Science Foundation to advance biomanufacturing capabilities. Keasling's industrial work also touched on supply-chain considerations relevant to China, India, Brazil, European Union, and United States markets.
Keasling has received numerous recognitions including election to the National Academy of Engineering, the National Academy of Sciences, and fellowship in the American Association for the Advancement of Science. He has been awarded prizes and honors presented by entities such as the Eli Lilly and Company, American Institute of Chemical Engineers, and the Royal Society of Chemistry. His contributions have been highlighted by awards connected to global health and innovation from organizations including the Bill & Melinda Gates Foundation, the MacArthur Foundation—through similar peer-recognized fellowships—and recognition from professional societies like the American Chemical Society and the Society for Industrial Microbiology and Biotechnology. Major institutional honors have come from his home institutions including chairs and endowed professorships at University of California, Berkeley and distinctions from Lawrence Berkeley National Laboratory.
Keasling has engaged extensively with policy and public discourse on biotechnology, participating in advisory roles for agencies such as the National Institutes of Health, the National Science Foundation, the Department of Energy, and international bodies including the World Health Organization. He has testified or advised legislative and executive offices in contexts involving biotechnology preparedness, biosecurity, and access to medicines, interfacing with forums attended by representatives from United States Congress, European Commission, and United Nations agencies. Keasling has contributed to outreach and education through collaborations with organizations such as the Bill & Melinda Gates Foundation, PATH, Doctors Without Borders, and academic initiatives at Berkeley Lab that connect to public-private consortia like the Joint BioEnergy Institute and BioMADE. He has lectured at venues including Royal Institution, Carnegie Institution for Science, American Association for the Advancement of Science meetings, and universities such as Harvard University, Yale University, Princeton University, Columbia University, and MIT, shaping discourse on innovation, access, and the societal implications of synthetic biology.
Category:American chemical engineers Category:Synthetic biologists